In that light, the IL-23/TH17 pathway is known to plays a dominant role in psoriasis immunopathogenesis, and it may not be surprising that clinical data increasingly show promise for IL17- and IL23-specificantibody species for treating immune-mediated inflammatory diseases, including psoriasis [10, 11, 12, 13].The critical role of the IL-23/TH17 axis in the pathogenesis of psoriasis-like lesions was confirmed experimentally in a murine model of psoriasis [14]. This evidence concerns the gene IL17A and psoriasis.